merck glp 1 agonist 20 Companies in Glucagon-Like Peptide-1 Agonists Market Size Merck & Co. signs license

GLP-1 medications address some of these limitations by modulating the reward value of food and slowing gastric emptying, which creates physical fullness independent of appetite suppression

B.SuhrsE.HermannT.MadsbadS.HolstJ

The disadvantage here is that one cannot distinguish between direct effects of the KO and side effects caused, for example, by different immune cell status or decreased caloric intake

That is creating much larger treatment effects much larger than what we ever imagined. This raises the bar Historically, large randomized controlled trials for anti-obesity medications and intensive lifestyle regimens have been considered clinically meaningful if they demonstrated at least 5% weight loss

10.2337/db13-0903 72 NunnE.JaiswalN.GavinM.UeharaK.StefkovichM.DrareniK.et al (2024)

95% CI, 3.34 to 4.21)